Metrics as of 10/14/2026, 08:31 AM (Berlin time), refresh in progress.
Solid Biosciences Stock
Solid Biosciences Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Alexander G. Cumbo
- Employees
- 121
- Market cap
- $593 M
- IPO
- 26/01/2018
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin…
Solid Biosciences stock: price history
1D
-3.7%
1W
-19.5%
1M
-36.6%
6M
-35.9%
YTD
-2.0%
1Y
-10.2%
2Y
-21.1%
5Y
-83.6%
10Y
–
Next earnings date
Next earnings date
02/11/2026 (in 16 days)
Volatility around earnings
~4% weaker price swings than usual
Ask the agents about Solid Biosciences
Analyst assessment of Solid Biosciences
PRICE TARGET LOW
US$16.00
CONSENSUS
US$20.50
MEDIAN
US$19.00
PRICE TARGET HIGH
US$26.00
0
STRONG BUY
18
BUY
5
HOLD
0
SELL
0
STRONG SELL
23
TOTAL · Buy
As of: 14/09/2026
Solid Biosciences stock metrics
P/E
-2.9
P/B
1.62
EV/EBITDA
-2.21
RETURN ON EQUITY
-14.6%
NET MARGIN
0.0%
DEBT/EQUITY
0.05
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
79.4%
FLOAT SHARES
78,198,714
AVG. DAILY VOLUME (30D)
1,406,381
Insider transactions (SEC)
SMITH IAN F
SMITH IAN F
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Solid Biosciences stock
What does Solid Biosciences do?
Solid Biosciences Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Alexander G. Cumbo, the company employs around 121 people.
The IPO was on 26/01/2018; the stock trades on NASDAQ under the ticker SLDB.
What do analysts say about Solid Biosciences stock?
23 analysts rate the stock, the consensus is Buy (as of 14/09/2026).
The average price target is US$20.50, ranging from US$16.00 to US$26.00, with a median of US$19.00.
This is an external assessment, not a statement by Market Jury.
When does Solid Biosciences report next?
The next earnings date is 02/11/2026.
Around past earnings, price swings were roughly -4% stronger than usual.
Does Solid Biosciences pay a dividend?
No, Solid Biosciences currently does not pay a dividend.
Which stocks are comparable to Solid Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Solid Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Solid Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.